[go: up one dir, main page]

MX2022001841A - Anticuerpos contra ilt2 y uso de los mismos. - Google Patents

Anticuerpos contra ilt2 y uso de los mismos.

Info

Publication number
MX2022001841A
MX2022001841A MX2022001841A MX2022001841A MX2022001841A MX 2022001841 A MX2022001841 A MX 2022001841A MX 2022001841 A MX2022001841 A MX 2022001841A MX 2022001841 A MX2022001841 A MX 2022001841A MX 2022001841 A MX2022001841 A MX 2022001841A
Authority
MX
Mexico
Prior art keywords
ilt2
methods
antibodies against
antibodies
compositions
Prior art date
Application number
MX2022001841A
Other languages
English (en)
Inventor
Tehila Ben-Moshe
Yair Sapir
Ilana Mandel
Avidor Shulman
Tsuri Peretz
Ziv Dana Haves
Ilana Goldshtein
Dror Alishekevitz
Anna Fridman-Dror
Motti Hakim
Original Assignee
Biond Biologics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biond Biologics Ltd filed Critical Biond Biologics Ltd
Publication of MX2022001841A publication Critical patent/MX2022001841A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención proporciona anticuerpos monoclonales o fragmentos de unión a antígeno de los mismos, contra ILT2, así como composiciones farmacéuticas que los comprenden y métodos para producirlos. También se proporcionan métodos para tratar el cáncer que comprenden administrar los anticuerpos o composiciones de la invención. También se proporcionan métodos de tratamiento de cáncer, tratamientos de combinación, y selección de pacientes.
MX2022001841A 2019-08-12 2020-08-12 Anticuerpos contra ilt2 y uso de los mismos. MX2022001841A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962885374P 2019-08-12 2019-08-12
US202063034569P 2020-06-04 2020-06-04
PCT/IL2020/050889 WO2021028921A1 (en) 2019-08-12 2020-08-12 Antibodies against ilt2 and use thereof

Publications (1)

Publication Number Publication Date
MX2022001841A true MX2022001841A (es) 2022-08-17

Family

ID=72474346

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022001841A MX2022001841A (es) 2019-08-12 2020-08-12 Anticuerpos contra ilt2 y uso de los mismos.

Country Status (15)

Country Link
US (2) US11236162B2 (es)
EP (1) EP4013510A1 (es)
JP (2) JP7284256B2 (es)
KR (2) KR20220116575A (es)
CN (1) CN114555637A (es)
AR (1) AR123212A1 (es)
AU (1) AU2020328931A1 (es)
BR (1) BR112022002579A2 (es)
CA (1) CA3150428A1 (es)
CO (1) CO2022002573A2 (es)
IL (1) IL290551A (es)
MX (1) MX2022001841A (es)
PH (1) PH12022550333A1 (es)
WO (1) WO2021028921A1 (es)
ZA (1) ZA202202363B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3150428A1 (en) 2019-08-12 2021-02-18 Biond Biologics Ltd. Antibodies against ilt2 and use thereof
EP4188430A4 (en) * 2020-07-28 2024-11-06 The Board Of Regents Of The University Of Texas System Monoclonal antibodies against lilrb1 for diagnostic and therapeutic use
US20230374127A1 (en) * 2020-07-28 2023-11-23 Lg Chem, Ltd. Anti-lilrb1 antibody and uses thereof
KR20230058074A (ko) 2020-08-12 2023-05-02 비온드 바이오로직스 엘티디 Ilt2에 대한 항체 및 이의 용도
BR112023018378A2 (pt) * 2021-03-11 2023-12-05 Univ Health Network Moléculas de ligação a lilrb1 e lilrb2 e usos para as mesmas
WO2023170434A1 (en) 2022-03-11 2023-09-14 Macomics Limited Compositions and methods for modulation of macrophage activity
US20250197500A1 (en) * 2022-03-29 2025-06-19 Coherus Biosciences, Inc. Methods of treating cancer
TW202436350A (zh) * 2023-02-02 2024-09-16 大陸商來凱醫藥科技（上海）有限公司 抗ｌｉｌｒｂ１及／或抗ｌｉｌｒｂ２抗體及其等用途
WO2024207855A1 (zh) * 2023-04-04 2024-10-10 成都优洛生物科技有限公司 抗lilrb1抗体或其抗原结合片段、制备方法和用途
WO2024260384A1 (en) * 2023-06-20 2024-12-26 Elpiscience (Suzhou) Biopharma, Ltd. Antibodies or antigen-binding fragments binding to lilrb1 and uses thereof
WO2025015190A1 (en) 2023-07-11 2025-01-16 Biond Biologics Ltd. Treatment of cancer with anti-ilt2 antibodies

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5719867A (en) 1995-06-30 1998-02-17 Scientific-Atlanta, Inc. Plural telephony channel baseband signal demodulator for a broadband communications system
US7803376B2 (en) 2003-07-24 2010-09-28 Innate Pharma S.A. Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds
EP3441403A1 (en) * 2005-12-20 2019-02-13 SBI Biotech Co., Ltd. Anti-ilt7 antibody
ES2437110T3 (es) 2006-11-14 2014-01-08 Genentech, Inc. Moduladores de la regeneración neuronal
CA2959821C (en) 2014-10-24 2024-10-29 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for inducing phagocytosis of MHC class I positive cells and for overcoming resistance to anti-CD47 agents/SIRPA
LT3405495T (lt) 2016-01-21 2021-08-10 Innate Pharma Inhibitorių kelių neutralizavimas limfocituose
TW201829463A (zh) 2016-11-18 2018-08-16 瑞士商赫孚孟拉羅股份公司 抗hla-g抗體及其用途
TWI796329B (zh) 2017-04-07 2023-03-21 美商默沙東有限責任公司 抗－ilt4抗體及抗原結合片段
EP3740224A4 (en) * 2018-01-18 2022-05-04 Adanate, Inc. ANTI-LILRB ANTIBODIES AND THEIR USES
BR112020024078A2 (pt) 2018-06-29 2021-02-17 Boehringer Ingelheim International Gmbh anticorpos anti-cd40 para uso no tratamento de doença autoimune
US20210301020A1 (en) 2018-07-24 2021-09-30 Amgen Inc. Combination of lilrb1/2 pathway inhibitors and pd-1 pathway inhibitors
US20220025045A1 (en) 2018-12-26 2022-01-27 Innate Pharma Compounds and methods for treatment of head and neck cancer
CA3150428A1 (en) 2019-08-12 2021-02-18 Biond Biologics Ltd. Antibodies against ilt2 and use thereof
US20240294634A1 (en) 2019-10-14 2024-09-05 Innate Pharma Treatment of cancer with ilt-2 inhibitors
CA3269788A1 (en) 2019-12-23 2025-10-30 Lg Chem, Ltd. Anti-lilrb1 antibody and uses thereof
BR112022021684A2 (pt) 2020-05-01 2023-01-17 Ngm Biopharmaceuticals Inc Agente de ligação, anticorpo que liga especificamente ilt2 e ilt4 humanos, agente de ligação ou anticorpo, anticorpo, composição farmacêutica, polinucleotídeo isolado ou polinucleotídeos, vetor ou vetores, célula isolada, método para interromper, inibir ou bloquear a ligação de ilt2 e/ou ilt4, método para interromper, inibir ou bloquear a supressão induzida por ilt2 e/ou ilt4, método para inibir ou diminuir a atividade de células supressoras, método para intensificar ou aumentar a atividade de célula, método para intensificar ou aumentar a atividade de linfócito t citolítico (ctl), método para interromper, inibir ou bloquear a atividade de ilt2 e/ou ilt4, método para interromper, inibir ou bloquear ilt2 ou supressão induzida por ilt4, método para inibir ou diminuir a atividade de mdsc, método para intensificar ou aumentar a atividade de ctl, método para tratar câncer em um sujeito, método para inibir o crescimento tumoral em um sujeito, método para aumentar ou intensificar uma resposta imune, método para inibir o relapso de tumor ou reaparecimento de tumor em um sujeito, método para induzir uma imunidade persistente ou a longo prazo, método para ativar células mieloides, uso do agente de ligação ou anticorpo, composição farmacêutica e combinação
KR20230058074A (ko) 2020-08-12 2023-05-02 비온드 바이오로직스 엘티디 Ilt2에 대한 항체 및 이의 용도

Also Published As

Publication number Publication date
AU2020328931A1 (en) 2022-03-24
WO2021028921A1 (en) 2021-02-18
AR123212A1 (es) 2022-11-09
CN114555637A (zh) 2022-05-27
KR20210096598A (ko) 2021-08-05
US20210277112A1 (en) 2021-09-09
CO2022002573A2 (es) 2022-06-21
BR112022002579A2 (pt) 2022-06-14
KR20220116575A (ko) 2022-08-23
EP4013510A1 (en) 2022-06-22
JP7284256B2 (ja) 2023-05-30
IL290551A (en) 2022-04-01
KR102433076B1 (ko) 2022-08-19
CA3150428A1 (en) 2021-02-18
US20220153836A1 (en) 2022-05-19
WO2021028921A9 (en) 2021-05-20
JP2023103385A (ja) 2023-07-26
JP2022536815A (ja) 2022-08-19
PH12022550333A1 (en) 2023-06-14
US12391755B2 (en) 2025-08-19
US11236162B2 (en) 2022-02-01
ZA202202363B (en) 2024-06-26

Similar Documents

Publication Publication Date Title
CO2022002573A2 (es) Anticuerpos contra ilt2 y uso de los mismos
CO2023002375A2 (es) Anticuerpos contra ilt2 y uso de los mismos
MX2019011117A (es) Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos.
MX2024007358A (es) Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y metodos para su uso.
MX2020004948A (es) Receptor de antígeno quimérico que selecciona como diana bcma, receptor de antígeno quimérico que selecciona como diana cd19 y terapias de combinación.
DOP2019000020A (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
CL2020002075A1 (es) Métodos para tratar el cáncer con anticuerpos anti-pd1.
MX2025003354A (es) Anticuerpos que se unen a 5t4
MX2019010848A (es) Composiciones y procedimientos para el tratamiento del cancer.
MX2019009772A (es) Anticuerpos anti-pd-1 para el tratamiento del cancer de pulmon.
MX2018012492A (es) Métodos para monitorear y tratar el cáncer.
CO2017000571A2 (es) Procedimiento de inactivación de inmunoglobulina endógena que permite facilitar procedimientos médicos que se ven afectados por la presencia de inmunoglobulina endógena
AR121599A1 (es) Anticuerpos
NI201500002A (es) Agentes de unión de rspo3 y usos de los mismos.
CO2021008665A2 (es) Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anti-cgrp o anti-cgrp-r
BR112019023909A2 (pt) método para tratamento de um paciente com câncer de ovário, câncer peritoneal ou câncer de trompa de falópio.
AR119507A1 (es) Anticuerpos triespecíficos anti-pd-1 / lag3 / tigit y anticuerpos biespecíficos anti-pd-1 / lag3
CL2019001749A1 (es) Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta.
AR115566A1 (es) Composiciones y procedimientos para el tratamiento del cáncer
BR112015027474A8 (pt) anticorpo, composição, método de tratamento do paciente que sofre de câncer e uso de um anticorpo.
BR112016023011A2 (pt) tratamento de câncer gástrico
MX2022001065A (es) Anticuerpo anti-bcma, fragmento de union al antigeno y uso medico del mismo.
CO2021016982A2 (es) Métodos de uso de una construcción biespecífica de unión al antígeno dirigida a her2 para el tratamiento de cánceres de las vías biliares
MX2022000082A (es) Composiciones terapeuticas y metodos para tratar canceres.
EA201990559A1 (ru) Комбинированная терапия